Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites by Watson NA et al.
ARTICLE
Kinase inhibition profiles as a tool to identify
kinases for specific phosphorylation sites
Nikolaus A. Watson 1, Tyrell N. Cartwright 1, Conor Lawless 2, Marcos Cámara-Donoso1, Onur Sen 1,
Kosuke Sako 3, Toru Hirota3, Hiroshi Kimura 4 & Jonathan M.G. Higgins 1✉
There are thousands of known cellular phosphorylation sites, but the paucity of ways to
identify kinases for particular phosphorylation events remains a major roadblock for under-
standing kinase signaling. To address this, we here develop a generally applicable method
that exploits the large number of kinase inhibitors that have been profiled on near-kinome-
wide panels of protein kinases. The inhibition profile for each kinase provides a fingerprint
that allows identification of unknown kinases acting on target phosphosites in cell extracts.
We validate the method on diverse known kinase-phosphosite pairs, including histone
kinases, EGFR autophosphorylation, and Integrin β1 phosphorylation by Src-family kinases.
We also use our approach to identify the previously unknown kinases responsible for
phosphorylation of INCENP at a site within a commonly phosphorylated motif in mitosis (a
non-canonical target of Cyclin B-Cdk1), and of BCL9L at S915 (PKA). We show that the
method has clear advantages over in silico and genetic screening.
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Protein phosphorylation is a vital regulatory system in cells,with 90% of all proteins undergoing phosphorylation1.Advances in phosphoproteomics mean that tens of thou-
sands of phosphorylation sites are now known2,3. Large catalo-
gues of specific phosphorylation events that occur within
particular cell types or organelles, or during specific treatments or
phases of the cell cycle, have been generated4–8. However,
understanding the biology controlled by a particular phosphor-
ylation event depends on being able to identify the kinase(s)
responsible for catalyzing it. Unfortunately, the methods available
for assigning kinase-phosphosite dependencies are limited. Con-
sequently, our ability to benefit from the expanding knowledge of
cellular phosphorylation is hampered.
Of the techniques that have been developed to interrogate
kinase-phosphosite dependencies, most focus on identifying the
targets of a kinase of interest; far fewer perform the similarly
valuable task of identifying the kinase(s) that phosphorylate a
particular residue within a substrate9. Indeed, we are not aware of
an experimental method that has found widespread use that can
selectively identify direct upstream kinases for any substrate.
Broadly, existing approaches can be divided into three categories:
(i) in silico predictions; (ii) screens in intact cells, and (iii) bio-
chemical methods, often using cell extracts or recombinant
kinases.
For a subset of kinases, consensus or optimal phosphorylation
motifs have been determined10–12. A known phosphosite can be
compared to these motifs to identify candidate kinases in silico13.
However, such motifs have been produced for only about half of
all human kinases and validated for far fewer. It is clear that false
positives and negatives are frequent using prediction methods,
even when combined with contextual information such as
protein-protein interaction data, co-expression, or co-occurrence
in literature abstracts11,14–16.
The second category includes techniques such as kinome-wide
RNAi, CRISPR/Cas9 or overexpression screens. Such screens are
tremendously useful to biologists, but they often identify path-
ways or networks of kinases that are indirectly required for
phosphorylation of a particular substrate rather than (or in
addition to) the direct kinase17–20. Indeed, these indirect effects
can make it difficult to identify the direct kinase for a particular
phosphorylation site. For example, if RNAi for a kinase impedes
cell cycle progression, it is difficult to determine whether its effect
on a substrate is direct21.
Finally, in the third category, a handful of approaches have been
outlined. Arrays of recombinant kinases can be tested for their
ability to phosphorylate substrates in vitro22, but such libraries are
incomplete, expensive, not widely available, and may not reflect the
activity state of kinases in cells. Co-immunoprecipitation or other
methods can be used to identify proteins that bind to substrates, but
these techniques are not specific for kinases, nor for particular
phosphosites, and kinase-substrate interactions may not be robust
enough to be detected. Methods that make use of modified forms of
substrates and/or ATP in an effort to crosslink substrates to their
cognate kinases in cell extracts are promising. However, where
tested, the specificity of kinase crosslinking has been low, these
approaches require additional steps such as mass spectrometry to
identify the crosslinked kinase23–25, and they have not yet been used
to identify unknown kinases. Tracking a specific kinase activity
through biochemical enrichment steps can also be carried out, but
this often requires large amounts of cell extract, multiple steps, and
protein sequencing methods to identify candidate kinases26–28.
Here, we develop a broadly applicable method to identify
kinases for specific phosphorylation sites that overcomes many of
these limitations. Our approach exploits the fact that, in recent
years, large numbers of kinase inhibitors have been profiled for
inhibitory activity on large panels of recombinant kinases29–34.
Conventional wisdom suggests small molecule inhibitors are not
appropriate tools for finding direct kinases because all such
inhibitors inhibit more than one target, and signaling cascades in
cells mean that indirect effects are common29. Our method,
however, which we term kinase inhibitor profiling to identify
kinases (KiPIK), circumvents these problems by treating the
inhibition information for each recombinant kinase as a finger-
print for the identification of kinases acting on target phos-
phorylation sites in cell extracts. In this way, rather than ignoring
or trying to minimize the influence of the off-target activity of
inhibitors, the approach exploits this information. Here we
describe the technique, validate it on diverse known kinase-
phosphosite pairs, and use it to identify cellular kinases for as yet
unassigned phosphosites on the Chromosomal Passenger Com-
plex protein INCENP and the transcriptional activator BCL9L.
Results
Rationale for the KiPIK method. KiPIK uses two key principles
to allow identification of direct kinases for particular phosphor-
ylation sites. First, it makes use of detailed selectivity profiles of
small molecule kinase inhibitors obtained using large panels of
recombinant kinases in vitro31–35. Together these provide unique
inhibition patterns, or fingerprints, for ~80% of human protein
kinases. Second, it utilizes the rapid action of kinase inhibitors in
cell extracts to focus on defined biological states and to minimize
indirect effects. The method relies on the finding that inhibition
profiles of kinase inhibitors in cell extracts are generally similar to
those established in vitro36–38. Like other approaches discussed
earlier, it also rests on the assumption that kinase reactions in cell
extracts preserve physiological kinase-phosphosite dependencies,
a notion with strong anecdotal support, including the observation
that extracts can carry out complex processes such as steps of the
cell cycle39–41.
In brief, KiPIK screening proceeds as follows (Fig. 1). Initially,
cell conditions in which the phosphorylation of a protein residue
of interest is robust are identified. For example, cells at a
particular cell cycle stage can be enriched, or a signaling pathway
leading to phosphorylation can be triggered. Whole-cell extracts
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Fig. 1 Outline of the KiPIK method. In KiPIK, cell extracts (red box) are
used as the source of all relevant kinases. Multiple kinase reactions are then
carried out using an exogenous substrate of interest, each in the presence
of single well-characterized kinase inhibitor (gray boxes) to produce an
inhibition fingerprint for the unknown kinase (blue box). Comparison of this
fingerprint with the known fingerprints of multiple kinases (orange box)
using Pearson correlation coefficients (green box) allows candidate kinases
to be ranked.
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of these cells are prepared in the presence of phosphatase
inhibitors to prevent the dephosphorylation of active kinases.
These cell extracts are then used as the source of all potentially
relevant kinases for in vitro kinase reactions using the substrate of
interest. Multiple such in vitro kinase reactions are carried out in
parallel, each in the presence of a member of a panel of well-
characterized kinase inhibitors. This yields an inhibition
fingerprint that characterizes the cellular kinase mainly respon-
sible for the observed phosphorylation. Finally, to identify
candidate kinases, this fingerprint is compared to the known
inhibition patterns of all kinases in the available profiling datasets.
The KiPIK method. An informative KIPIK screen requires a
library of kinase inhibitors for which in vitro inhibitory infor-
mation data is available across a range of recombinant kinases.
Suitable libraries include the protein kinase inhibitor sets (PKIS1
and PKIS2) which consist of published GlaxoSmithKline com-
pounds selected by the Structural Genomics Consortium34,35 and
a library of inhibitors assembled by a team at EMD Millipore32
and expanded at the Fox Chase Cancer Center31. The inhibitory
properties of compounds in these libraries have been determined
on large kinase panels in vitro using radiolabeled ATP incor-
poration assays31,32, substrate electrophoretic mobility shift
assays34, or inhibitor binding assays33–35. Together, these profiles
provide inhibition fingerprints for kinases encoded by 416 of the
~535 human protein kinase genes (Supplementary Data 1)1,42.
A cell extract containing the phosphorylation activity being
screened must also be prepared. In principle, any cell or tissue
could be used as a source, but here we have focused on cultured
cell lines. Prior to lysis, the cells can be treated to enhance the
phosphorylation signal, or to probe phosphorylation dependen-
cies in a particular context. For example, when investigating a
mitotic phosphorylation, enriching the mitotic cell population by
nocodazole treatment may be beneficial, while EGF stimulation
can be used to explore phosphorylation downstream of EGFR.
After lysis in the presence of phosphatase inhibitors, extracts are
immediately flash frozen. A number of methods are available to
assay substrate phosphorylation in cell extracts and a number of
these are likely to be compatible with the KiPIK procedure. Here,
we have used short biotinylated peptides encompassing phos-
phosites of interest as substrates, coupled with the use of
phospho-specific antibodies to detect peptide phosphorylation in
enzyme-linked immunosorbent assays (ELISA).
Using microplate robotics, many extract kinase reactions can
be performed in parallel, each in the presence of a single kinase
inhibitor from the characterized inhibitor library. Quantification
of substrate phosphorylation in the presence of each inhibitor
yields the required inhibition fingerprint that is characteristic of
the predominant kinase acting on the substrate in the extract.
This fingerprint is then compared with the known inhibition
patterns previously determined for recombinant kinases chal-
lenged with the same set of kinase inhibitors. The kinase(s) with
inhibition patterns showing the highest similarity to that of the
unknown kinase activity (determined using Pearson’s correlation
coefficient, ρ) are the top hits in the screen.
KiPIK for the histone H3S28 kinase identifies Aurora B. To
validate this methodology, we sought to identify the direct kinase
responsible for histone 3 serine 28 (H3S28) phosphorylation in
mitosis, previously reported to be Aurora B43. We made use of
312 kinase inhibitors from the PKIS1 panel (Supplementary
Data 2) that have been profiled in vitro on two panels of
recombinant kinases: a Nanosyn assay assessed inhibition of 203
kinases at inhibitor concentrations of 0.1 µM and 1 µM, whereas a
DSF (differential scanning fluorimetry) assay assessed inhibitor
binding at 1 µM to 68 kinases by thermal denaturation34. Toge-
ther, this provided coverage of 236 kinases (encoded by 234
unique genes). Extracts of HeLa cells that had been arrested in
mitosis for 12 h in nocodazole were used as the source of relevant
kinases. To create an inhibition fingerprint for the H3S28 kinase,
the phosphorylation of an H3(21–44)-GK-biotin peptide was
assayed using anti-H3S28ph antibodies in the presence of each
inhibitor individually at 10 µM. For the H3S28 kinase fingerprint,
the top three correlation scores were all from the Nanosyn 1 µM
profiling dataset, and all were with Aurora family kinases (Fig. 2a;
Supplementary Fig. 2). The highest overall correlation (ρ= 0.74)
was with Aurora B. Notably, the top three hits within the
Nanosyn 0.1 µM dataset were also all Aurora kinases. The DSF
dataset did not contain the Aurora kinases, and no kinase in this
dataset had a correlation score above 0.52. Therefore, the KiPIK
method unambiguously identified Aurora family kinases as those
most likely responsible for H3S28 phosphorylation in mitosis.
Aurora B, the established kinase, was the top hit.
KiPIK screens for tyrosine phosphorylation sites. We wished to
validate KiPIK screening for diverse kinases. We, therefore,
conducted further screens to identify kinases for two tyrosine
residues. The first was Y795 in the cytoplasmic tail of integrin
β1A, thought to be phosphorylated by Src family kinases44, and
the second was the Y1016 autophosphorylation site in the
carboxy-terminal tail of EGFR (Y992 in mature EGFR)45,46. In
both cases, we used generic phospho-tyrosine antibodies to detect
phosphorylation of biotinylated substrate peptides in extracts of
A431 cells treated for 5 min with 50 ng/ml EGF, and the PKIS1
library of kinase inhibitors.
In the screen for kinases that phosphorylate integrin β1A Y795,
the top 6 hits, and 10 of the top 11 overall, were members of the
Src family kinase family (Fig. 2b, Supplementary Fig. 3). There-
fore, this screen unambiguously identified members of the Src
family as candidate kinases responsible for integrin β1 Y795
phosphorylation, strongly supporting previous suggestions. In the
screen for kinases that phosphorylate residue Y1016 of EGFR,
there were three clear candidates (Fig. 2c, Supplementary Fig. 4).
The top hit was EGFR, and the two EGFR-related kinases ERRB2/
HER2 and ERRB4/HER4 were second and third. Therefore, the
KiPIK method successfully identified EGFR as the top candidate
kinase for autophosphorylation of Y1016.
These results demonstrate that, for peptides containing a single
tyrosine, generic phospho-specific antibodies can be used
effectively for KiPIK screening, avoiding the need for
phosphosite-specific antibodies. They also lend further support
to the idea that the method can be used successfully to identity
kinases for a variety of specific phosphorylation sites, including
on receptor and non-receptor tyrosine kinases as well as on a
mitotic serine/threonine kinase.
KiPIK screening preferentially identifies direct kinases. To
substantiate the idea that KiPIK screens are less susceptible to
indirect upstream kinase activity than genetic screens, we turned
to a kinase that we know is under the control of an upstream
kinase (Aurora B) that is active in KiPIK conditions. Haspin is the
direct kinase that phosphorylates Histone H3T3 during mitosis47.
However, in cells, Aurora B inhibition also reduces H3T3ph
because Aurora B activates Haspin and inhibits the RepoMan-
PP1 phosphatase that dephosphorylates H3T3ph41,48. In contrast,
in cell extracts containing phosphatase inhibitors, Aurora B
inhibitors do not compromise generation of H3T3ph41, pre-
sumably because Haspin is already phosphorylated and activated,
and phosphatases are inactive. Consistent with this, when we
carried out a kinome-wide RNAi screen to identify kinases
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required for H3T3ph in mitotic HeLa cells, Haspin was the top
hit, but Aurora B kinase was also identified in the top 3 (Fig. 3a).
However, when we conducted a KiPIK screen using a H3(1–21)
peptide to identify the kinase responsible for phosphorylating
H3T3 in mitotic HeLa extracts (Fig. 3b, Supplementary Fig. 5),
none of the Aurora family kinases was within the top 40 (highest
ρ= 0.32), while Haspin was the top hit (ρ= 0.66). In addition,
the kinase Plk1, which also has a role in activating Haspin in
cells49,50, was in the top 5 protein kinase hits in the RNAi screen
but was in the bottom 20% of the KiPIK screen. Therefore, when
compared to an RNAi screen, a KiPIK screen for H3T3ph was
relatively insensitive to the kinases upstream of the direct kinase.
EGFR and Src family kinases participate in intimate crosstalk
in A431 cells. Src family kinases are activated in response to
EGFR signaling in these cells, and EGFR inhibitors prevent Src
activation51–53. In addition, active Src family kinases can feed
back to activate EGFR54–56. When we conducted KiPIK screens
in EGF-stimulated A431 extracts for the Src-family substrate
integrin β1A Y795, EGFR was present among the top ten kinases
(Fig. 2b). Similarly, several Src family kinases were found in the
top twenty hits when we conducted a KiPIK screen for the EGFR
autophosphorylation site on Y1016 (Fig. 2c). Nevertheless, as
described earlier, KiPIK unambiguously identified Src family
kinases as the top candidates for integrin β1A Y795 phosphor-
ylation, and EGFR as the top candidate for autophosphorylation
at Y1016.
Together, these results demonstrate that KiPIK screening
identifies the direct kinase responsible for a particular
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Fig. 2 Results of KiPIK screens using the PKIS1 inhibitor library. a H3S28ph, b Integrin β1A Y795ph, and c EGFR Y1016ph. In each case, stripcharts on the
left show the Pearson correlation coefficients between the %inhibition results from the KiPIK screen and the % inhibition results for each of the kinases in the
Nanosyn profiling datasets at 0.1 and 1 µM, and the DSF profiling dataset. The tables on the right show the top 10 (or 11) hits from each profiling dataset with
corresponding correlation coefficients (ρ) and z-scores. Expected kinase(s) are shown in red, and closely related kinases in green. Note that Aurora kinases are
not present in the DSF dataset, and Src and EGFR-related kinases are not present in the Nanosyn datasets. Source data are provided as a Source Data file.
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phosphorylation event and is relatively insensitive to the indirect
effect of kinases operating in signaling networks.
KiPIK identification of a kinase for INCENP S446. We next
sought to use KiPIK identify the kinase for an unassigned
phosphosite. We were intrigued by consensus motifs, identified
using mass spectrometry by Dephoure et al.4, which are com-
monly phosphorylated in mitosis but for which the responsible
kinase(s) were not identified. For one of these motifs, P-X-pS-X-
X-[K/R], we identified a site in the Inner Centromere Protein
(INCENP) for which a phosphospecific antibody had been raised:
INCENP S446ph57. Phosphorylation of this site was previously
shown to be sensitive to the Aurora B inhibitor Hesperadin57, but
this inhibitor is relatively non-selective58 and the site does not
match the classical Aurora kinase consensus. To identify the
kinase responsible for phosphorylation of this site, we conducted
a KiPIK screen using a biotin-INCENP(439–453) peptide
(GPREPPQSARRKRSY), and extracts of mitotic HeLa cells as a
source of kinases. This screen unambiguously identified Cyclin-
dependent kinases as the best hits in all three profiling datasets.
The master regulator of mitosis, Cyclin B1-Cdk1, was the top hit
(ρ= 0.81; Fig. 4a, Supplementary Fig. 6).
To confirm that Cyclin B1-Cdk1 was a bona fide kinase for
INCENP S446, we first conducted in vitro kinase assays. Indeed,
Cyclin B1-Cdk1 efficiently phosphorylated S446 on a recombi-
nant INCENP fragment containing residues 369–583, but not the
TSS motif (S893/S894) in recombinant INCENP residues
825–918. In contrast, Aurora B was able to phosphorylate its
known target, the TSS motif of INCENP, but not S446 (Fig. 4b).
Full length recombinant INCENP was also phosphorylated by
Cyclin B1-Cdk1 in vitro (Supplementary Fig. 7A). Furthermore,
INCENP immunoprecipitated from nocodazole-arrested mitotic
cells was recognized by the INCENP S446ph antibody, and this
phosphorylation was sensitive to the Cdk inhibitor Roscovitine
(Supplementary Fig. 7B). However, determining the direct
substrates of Cyclin B1-Cdk1 in cells is complicated because
inhibition of Cdk1 prevents mitotic entry and/or forces mitotic
exit, leading to indirect effects on multiple kinase substrates. To
address this, we used immunofluorescence microscopy and high
content imaging to analyze the kinetics with which INCENP
S446ph was lost following acute Cdk inhibition in nocodazole-
arrested mitotic cells. The proteasome inhibitor MG132 was also
included because it prevents the degradation of key mitotic
regulators such as Cyclin B1 and, in some instances, is reported to
delay mitotic exit even in the presence of Cdk1 inhibitors59.
Aurora B relocates to the spindle midzone at the end of mitosis
so, as an additional way to focus on cells still in mitosis, we
analyzed only cells in which Aurora B remained on chromo-
somes. We found that Cdk1 inhibition using 10 µM RO-3306 led
to a 50% reduction in intensity of INCENP S446ph over 9 min,
while the Aurora B phosphorylation site INCENP TSS was
unaffected (Fig. 4c). In contrast, inhibition of Aurora B with
10 µM ZM447439 led to a rapid decline of INCENP TSSph but
did not influence INCENP S446ph over the same time period
(Fig. 4c). Also consistent with Cyclin B1-Cdk1 being the kinase
responsible, INCENP S446ph was detected on chromosomes in
mitotic cells from early mitosis until metaphase when Cyclin B1-
Cdk is active, but was lost at anaphase when Cyclin B is degraded
(Fig. 4d). This pattern mirrored that of previously reported Cyclin
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Fig. 3 Results of RNAi and KiPIK screens for H3T3ph. a A kinome-wide RNAi screen for H3T3ph in mitosis was carried out in HeLa cells using
immunofluorescence and High Content Analysis. The stripchart on the left shows the standard score (proportional to staining intensity) for each protein
kinase in the library. The table on the right shows the top 10 protein kinase hits from the screen with corresponding standard scores. b Results of a KiPIK
screen using the PKIS1 inhibitor library for H3T3ph. The stripcharts on the left show the Pearson correlation coefficients with each kinase in the Nanosyn
profiling datasets at 0.1 and 1 µM, and the DSF profiling dataset. The table on the right shows the top 10 hits from each profiling dataset with corresponding
correlation coefficients and z-scores. The expected kinase (Haspin/GSG2) is shown in red, and kinases that are known to indirectly modulate H3T3ph are
shown in blue. Note that Haspin/GSG2 is not present in the Nanosyn datasets. Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15428-0 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1684 | https://doi.org/10.1038/s41467-020-15428-0 |www.nature.com/naturecommunications 5
CDK1-Cyclin B
Other Cyclin-dependent kinases
Co
rre
la
tio
n 
co
ef
. (
)
INCENP S446ph
a
INCENP
TSSph Aurora B DNA Merge
INCENP
S446ph Aurora B DNA Merge
b
c
d
-70
55
70
55
1.0
Cdk1 inhibitor
RO-3306
Aurora B inhibitor
ZM447439
0.5
0.0
Time in inhibitor/min
INCENP S446ph/Aurora B
INCENP TSSph/Aurora B
R
el
at
ive
 fl
uo
re
sc
en
ce
 in
te
ns
ity
0 3 6 9 0 3 6 9
1.0
0.5
0.0
–0.5
Na
no
syn
 0.
1 μ
M
Na
no
syn
 1 
μM DS
F 
-
-
-
INCENP S446ph
INCENP TSSph
Silver stain
No
ne
Cy
cli
n 
B1
-C
dk
1
Au
ro
ra
 
B-
IN
bo
x
No
ne
Cy
cli
n 
B1
-C
dk
1
Au
ro
ra
 
B-
IN
bo
x
+ATP – ATP
INCENP(369–583)
INCENP(825–918)
INCENP(369–583)
INCENP(825–918)
Nanosyn 0.1 μM Nanosyn 1 μM DSF
Rank Kinase Kinase Kinase zzz
1 CDK2-cyclinA 0.681 11.9 CDK1-cyclinB 0.807 14.5 CDK9 0.709 13.0
2 CDK1-cyclinB 0.652 11.4 CDK2-cyclinA 0.798 14.3 CDK2 0.683 12.5
3 CDK5-p35 0.647 11.3 CDK5-p35 0.796 14.3 STK16 0.576 10.5
4 GSK3B 0.639 11.1 CDK2-cyclinE 0.779 14.0 STK17A/DRAK1 0.554 10.1
5 CDK2-cyclinE 0.638 11.1 CDK3-cyclinE 0.750 13.5 PCTK2/CDK17 0.545 9.98
6 GSK3A 0.627 10.9 CDK4-cyclinD 0.728 13.1 CLK4 0.534 9.77
7 CDK3-cyclinE 0.580 10.1 CDK6-cyclinD3 0.688 12.4 CDKL1 0.532 9.74
8 CDK4-cyclinD 0.571 10.0 GSK3A 0.651 11.7 STK17B/DRAK2 0.496 9.09
9 CDK6-cyclinD3 0.547 9.54 GSK3B 0.649 11.7 PRKAA2 0.477 8.74
10 DYRK1A 0.478 8.34 DYRK1B 0.569 10.2 AAK1 0.459 8.41
kDa
Fig. 4 Results of a KiPIK screen for INCENP S446ph, and confirmatory experiments. a The stripcharts on the left show the Pearson correlation
coefficients with each kinase in the Nanosyn profiling datasets at 0.1 and 1 µM, and the DSF profiling dataset. The table on the right shows the top 10 hits
from each profiling dataset with corresponding correlation coefficients and z-scores. The overall top hit kinase is shown in red, and closely related kinases
in green. Note that Cdk1 is not present in the DSF dataset. b Recombinant Cyclin B-Cdk1 efficiently phosphorylates INCENP S446, but not INCENP TSS,
in vitro. Recombinant INCENP(369–583) and INCENP(825–918) were provided as potential substrates for GST-CDK1/GST-CycB or Aurora B/INbox and
phosphorylation was detected using the corresponding phosphospecific antibodies. The experiment was done twice with similar results. c Acute inhibition
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which Aurora B was on chromatin were analyzed. Error bars show means ± SD (n= 3 separate cell cultures treated in parallel). d Immunofluorescence
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B1-Cdk1 target sites on INCENP, but was distinct from that of
INCENP TSSph (Fig. 4d) which is generated by Aurora B activity
throughout mitosis, including on the central spindle in
anaphase60. Together, these results show that Cyclin B-Cdk1 is
the primary direct kinase for INCENP S446 in cells, and that
KiPIK can identify the kinases required for the generation of
orphan phosphorylation sites.
Inhibitor library requirements for KiPIK screening. We have
shown that a single inhibitor panel, PKIS1, is suitable for use in
KiPIK screening. We wished to determine if additional inhibitor
panels and profiling datasets could be utilized. Where alternative
inhibitor panels have been profiled on additional kinases, this
allows the number of kinases covered by KiPIK screening to be
increased. Furthermore, not all kinase inhibition profiles are
necessarily concordant between different profiling efforts61, and
the extent to which different compound sets give similar results
provides an indication of the robustness of the method.
To explore this, we assembled a custom library of 128 inhibitors
that have been used in other kinase profiling studies (Supplemen-
tary Data 3). This included all 72 inhibitors profiled on 388 different
kinases by Davis et al. (“Davis”) using the DiscoverX competition
binding assay33, 76 of the 178 inhibitors profiled at 0.5 µM on 300
kinases by Anastassiadis et al. (“Anastassiadis”) using conventional
in vitro kinase assays at a fixed concentration of 10 µM ATP31, and
55 of the 158 inhibitors profiled at 1 µM or 10 µM on 234 kinases
by Gao et al. (“Gao 1 µM” and “Gao 10 µM”), also using in vitro
kinase assays, but at near-Km concentrations of ATP32. Together,
this encompasses 431 kinases (405 unique human kinase genes;
Supplementary Data 1).
Using this library, we repeated KiPIK screens for mitotic H3T3
and H3S28 phosphorylation. For H3T3ph, the highest overall
correlation coefficient (ρ= 0.69) was with Haspin in the Gao 1
µM dataset, and Haspin was also the top scoring kinase (ρ= 0.66)
in the Anastassiadis dataset. Haspin was not present in the Davis
dataset, and no kinase in this panel had a correlation coefficient
exceeding 0.52 (Fig. 5a). As before, the upstream regulatory
kinases for Haspin, Plk1 and Aurora B, did not score highly in the
screen (Fig. 5a). For H3S28ph, the highest overall correlation
coefficient (ρ= 0.78) was with Aurora B in the Davis dataset, and
Aurora B was also the top scoring kinase (ρ= 0.66) in the
Anastassiadis dataset (Fig. 5b). Therefore, KiPIK screening with
alternative inhibitor and kinase panels was able to accurately
identify the appropriate kinase for both sites.
In the H3S28ph screen, the three Aurora kinases were all in the
top 25 kinases in the Gao 1 µM dataset, but they were not ranked
as highly in the Gao 10 µM dataset. In the H3T3ph screen,
Haspin was the third highest-scoring kinase in the Gao 10 µM
dataset. One likely reason for poorer performance in these three
cases was apparent when the KiPIK correlation plots for Haspin
and Aurora B in the Gao datasets were examined (Supplementary
Fig. 8): it was clear that more of the Haspin and Aurora B
inhibitors in the Gao datasets caused near 100% kinase inhibition
than in our KiPIK screening data. This decreased the linearity of
the correlation plots, and so reduced the correlation coefficients.
This highlights the importance of using suitable inhibitor
concentrations in both KiPIK and profiling studies.
A second likely reason for the varying utility of profiling
datasets was the different number of inhibitors we tested from
each (Fig. 5; 310 for Nanosyn, 311 for DSF, 76 for Anastassiadis,
72 for Davis, 55 for Gao). To more formally test the impact of
inhibitor panel size, for those KiPIK screens where a clear single
kinase was identified as the expected top hit (For H3T3ph: DSF,
Anastassiadis, Gao 1 µM; for H3S28ph: Nanosyn 1 µM, Anastas-
siadis, Davis; and for EGFR Y869ph: Nanosyn 0.1 µM and 1 µM),
we downsampled the inhibitor panel size by computationally
removing random but fixed numbers of inhibitors. This analysis
revealed that, when using large inhibitor panels, the identification
of the correct kinase was generally robust until the inhibitor
library size decreased below about 100 inhibitors (Supplementary
Figs. 9, 10). Consistent with this, for the smaller panels of
inhibitors, identification of the correct kinase fell off quickly as
the numbers of inhibitors used decreased. It is therefore
unsurprising that the smallest inhibitor panel used (for the Gao
dataset) is the least robust. Nevertheless, the results suggest that
the use of more inhibitors is likely to increase the utility of these
additional datasets.
Given these considerations, it would be useful to have a simple
metric to allow the robustness of different screens to be
compared, taking into account the number of inhibitors used
and the strength of observed correlation coefficients. We
estimated the null distribution of correlation coefficients for each
screen by random permutation of % inhibition results (Supple-
mentary Fig. 11A), and then calculated z-scores for each
experimentally-determined correlation coefficient, reflecting
how many standard deviations each is from the mean of the
null distribution (Supplementary Fig. 11B, C; z-scores are also
provided in Figs. 2–6). While the z-score does not correct for all
the factors contributing to inter-assay variation, it appears that
screens in which the top z-scores are below 6 should be treated
with caution, while z-scores of 10 or above appear robust.
An alternative inhibitor library identifies a BCL9L kinase.
While this work was in progress, a new set of 485 inhibitors,
PKIS2, profiled at 1 µM using the DiscoverX assay became
available35. The dataset covers 403 human kinases encoded by
389 unique genes. We used this new library to identify the kinase
for an unassigned phosphorylation site. Specifically, we examined
phosphorylation of S915 in the transcriptional activator BCL9L
(B-cell lymphoma 9-like protein), a phosphosite identified by
mass spectrometry among proteins enriched using a phospho-
AMPK substrate motif (L-X-R-X-X-[pS/pT]) antibody62. BCL9L
S915ph is upregulated by phorbol ester treatment (see Cell Sig-
naling Technology; https://www.cellsignal.co.uk/products/
primary-antibodies/phospho-bcl9l-ser915-antibody/13325), sug-
gesting that it lies within a PKC-triggered signaling pathway. To
identify the relevant direct kinase, we conducted a KiPIK screen
using 399 PKIS2 inhibitors, a biotin-BCL9L(908–922) peptide,
extracts of TPA-treated HeLa cells as a source of kinases, and an
anti-BCL9L S915ph antibody. This screen clearly identified the
AGC kinase family as the source of the best hits (the top 20 are all
AGC kinases). The top hit was the cAMP-dependent kinase PKA-
β (ρ= 0.87) and PKA-α was also within the top ten, as were PKC-
δ, -η and -ε. To test the robustness of the screen, we repeated it
using all 485 available PKIS2 inhibitors and PKA-β was again the
top hit (ρ= 0.77; Fig. 6a, Supplementary Fig. 12).
Further experiments confirmed that: (i) RNAi of PKA-α/β
diminished BCL9L S915 phosphorylation in TPA-stimulated HeLa
cells (as did RNAi of phorbol-ester-sensitive PKC isoforms, as
expected; Fig. 6b); (ii) Forskolin, which activates PKA by
stimulating cAMP production63, increased BCL9L S915ph in cells
(Fig. 6c), (iii) a small molecule that inhibits PKA, but not PKC (H-
89)29,31,32, decreased the phosphorylation of BCL9L S915 in cells
and, as expected, a PKC inhibitor (Gö 6983)31,32 also decreased
BCL9L S915ph, while inhibitors with activity against AKT and
LATS kinases (MK-2206 and SU-14813, respectively)33,64 did not
(Fig. 6d); (iv) BCL9L S915 peptides were more strongly
phosphorylated by recombinant PKA-α than by PKC-δ in vitro
(Fig. 6e); and (v) PKA-α but not PKC-δ phosphorylated full-length
immunoprecipitated BCL9L S915 (Fig. 6f). Together, these results
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Fig. 5 Results of KiPIK screens using the custom inhibitor library. a KiPIK screen for H3T3ph. Stripcharts show the Pearson correlation coefficients of the
%inhibition results from the KiPIK screen against the %inhibition results for each of the kinases in the Anastassiadis, Davis and Gao (1 and 10 µM) profiling
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Source data are provided as a Source Data file.
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indicate that KiPIK using the PKIS2 library correctly identified PKA
as the direct BCL9L S915 kinase in HeLa cells, even where the
apparent upstream kinase PKC was strongly activated by phorbol
ester treatment.
Alternative approaches to analyse correlation data. In cases
where the kinase of interest is present in the profiling dataset, we
have shown that KiPIK is able to identify the correct kinase or
kinase sub-family in the six cases we have tested. However,
because only 80% of known protein kinases are covered by the
profiling data it is possible, for some screens, that the unknown
kinase is not present in the profiling data. Nevertheless, the top
hits are still likely to share properties with the unknown kinase,
and therefore can help prioritize candidate kinases for further
study. As we have shown above, a simple ranking of correlation
coefficients readily identifies relevant candidates, but we explored
two additional approaches to enhance this analysis.
First, the well-known sequence-based kinome dendrogram of
Manning et al.42 can be annotated with correlation coefficients
derived from KiPIK screening (Figs. 7 and 8, and Supplementary
Figs. 13–20). This allows kinases that are closely related in
sequence to the top hits in the screen to be easily located, and
sub-families of kinases for further testing can then be identified.
For example, the DSF profiling set does not contain the kinase
Cdk1, but strong hits on the cyclin-dependent kinase (CDK) sub-
branch of the CMGC kinase family clearly highlight the CDK
sub-family as a source of excellent candidates for the INCENP
S446ph kinase (Fig. 8a, Supplementary Fig. 19).
Second, hierarchical clustering of all kinases based on the
similarity of their inhibition fingerprints can be carried out (using
Pearson correlation coefficients). This generates kinome trees in
which kinases are clustered more closely if they are inhibited by
similar sets of inhibitors (Supplementary Figs. 21–28). As
previously described, such inhibition-based trees have general
similarities to sequence-based trees, but also notable differences,
such as separating the p38α and p38β kinases from the closely-
related p38δ and p38γ kinases58,65. A caveat of this approach is
that, although bootstrapping gives an indication of the reliability
of the branching pattern (Supplementary Figs. 29–32), a kinase
can only be in one place in a tree, so alternative possible kinase
clusters are obscured. Nevertheless, if the inhibition fingerprint of
the unknown kinase is included in the clustering process, then
kinases that have similar inhibition profiles, but may be distant in
sequence relatedness, can be identified. For example, Haspin is
not present in the Davis profiling set, but the inhibition
fingerprint of H3T3ph kinase activity clusters in a group that
contains DYRK2 (Supplementary Fig. 22A). This kinase is a
common off-target of Haspin inhibitors66–68 and it clusters close
to Haspin in profiling sets which do contain both Haspin and
DYRK2 (ie Anastassiadis and Gao 1 µM; Supplementary Fig. 22B).
In this way, information derived from the properties of kinases
and inhibitors that were not included in the experimental
screening process can be exploited to identify kinases for further
testing.
Discussion
Here we describe a method for identifying the kinases for specific
protein phosphorylation sites that outperforms in silico and
genetic screening approaches in key respects. KiPIK identified the
previously determined kinase for all examples we tested, includ-
ing serine/threonine kinases that act on histones in mitosis, and
both receptor and non-receptor tyrosine kinases. We also tested
the method on two orphan phosphorylation sites. For a residue in
the Chromosomal Passenger Complex protein INCENP (S446)
that sits within a consensus motif commonly phosphorylated in
mitosis by unknown kinase(s)4,57, KiPIK unambiguously identi-
fied Cyclin-dependent kinases as candidates, and Cyclin B1-Cdk1
was the top hit. Follow up studies supported the view that this
kinase is responsible for INCENP S446ph in cells. Together, these
results suggest that the P-X-S-X-X-[K/R] motif is a common non-
canonical target for Cdk1 action in mitosis, an idea supported by
findings that such motifs are favorable in vitro targets for Cyclin
B-Cdk169. S446 lies within a region of INCENP (PRD1) that has
recently been shown to be heavily phosphorylated by Cyclin B1-
Cdk1 on other residues, and therefore may be an additional site
that modulates the association of INCENP with microtubules70.
We also found that, after phorbol ester treatment of cells, PKA
can phosphorylate S915 of BCL9L. This is consistent with find-
ings that phorbol esters can trigger PKA activity, perhaps via the
phosphorylation of adenylate cyclase by PKC63. BCL9L functions
in the Wnt signaling pathway by interacting with β-catenin to
promote TCF-mediated transcription71,72. Our findings suggest
that it may be fruitful to investigate if phosphorylation of BCL9L
by PKA, as well as the reported phosphorylation of β-catenin by
PKA73,74, underlies crosstalk between PKA and Wnt signaling75.
KiPIK has a number of advantages over current methods for
identifying kinases for phosphorylation sites. For example, bio-
chemical approaches that exploit substrate-kinase interactions or
attempt kinase purification by tracing enzyme activity require
large samples and customized methods that are not easily
transferable to additional substrates. In contrast, KiPIK is a
relatively standardized approach that can be applied to a variety
of substrates. Methods such as RNAi and CRISPR/Cas9 (or
overexpression) can be used, but they require long timeframes,
causing indirect effects and limiting analysis at different stages of
a process such as the cell cycle. These methods also require
efficient transfection, and genetic manipulation prohibits simple
analysis of the latter stages of a cellular or developmental process
if there is a defect in an earlier step. Small molecule inhibitors, in
contrast, act in minutes and can be used to determine the effect of
kinase inhibition on a particular biological state without affecting
a preceding step. A recently published approach using inhibitor
panels in intact cells appears useful, but it identifies networks of
kinases upstream of substrate phosphorylation events76. Our
method differs substantially from this because it utilizes extracts
of cells harvested in a state where signaling pathways are already
active and the presence of phosphatase inhibitors minimizes the
requirement for the ongoing activity of upstream kinases, biasing
KiPIK towards identification of the direct kinases for particular
substrate residues. This allows, for example, the successful iden-
tification of Cyclin B1-Cdk1 as a direct kinase for INCENP S446
kinase, even though loss of Cdk1 prevents cells from entering
mitosis21, and allows the direct and indirect contributions of
Haspin and Aurora B to H3T3ph to be uncoupled. Inhibitors also
allow analysis of a broad range of cells and tissues which may be
difficult to transfect. In addition, numerous kinases have kinase-
activity-independent functions, and inhibitors provide a powerful
way to focus on the function of kinase activity. In practice,
however, many kinase inhibitors are poorly selective, and this
significantly hampers their use in conventional screening
approaches. In KiPIK screening, however, we harness knowledge
of this incomplete selectivity to enhance the information content
of inhibitor screens to identify candidate kinases for particular
phosphorylation sites.
KiPIK has a number of theoretical advantages over in silico
approaches. In particular, it utilizes cell extracts and so provides
biological context that is absent from most prediction methods.
For KiPIK, cells can be treated prior to extract preparation to
ensure that the relevant kinase and its regulatory subunit(s) are
present and active, and over 400 human kinases are currently
covered by the method. Kinases that are not expressed in the
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relevant cell are excluded, and only kinases that efficiently
phosphorylate the substrate in competition with other kinases
and substrates in the extract will be identified. In contrast, the
majority of computational methods are limited in the number of
kinases for which they can make predictions, and they do not
account for factors such as the activation state or expression level
of the kinase14. Indeed, compared with a spectrum of in silico
prediction methods, including those that attempt to integrate
information on biological context, KiPIK was the most reliable
approach for identifying the kinases for the six substrates
examined here (see Supplementary Fig. 33).
As with all screening approaches, there are limitations of the
KiPIK method. Although the inhibitor libraries we have used
contain inhibitors for the great majority of kinases31,32,34, we
cannot be sure that all kinases are equally discoverable. For an
individual screen, KiPIK provides an unambiguous ranking of
candidate kinases that can be followed up with additional
experiments. In addition, z-scores provide an indication of the
robustness of the results. Screens in which all z-scores are below 6
may be questionable, but future utilization of the method should
allow this boundary to be refined. The coverage of the human
kinome is approximately 80%, but there remain over 100 kinases
for which in vitro inhibition profiles are unknown. The combi-
nation of KiPIK screening data with sequence or inhibition-based
dendrograms (Fig. 7 and Supplementary Fig. 22) can alleviate this
problem, but profiling of additional kinases with existing inhi-
bitor panels will be the best way to increase the coverage of the
kinome. The method also requires that the physiological kinase is
the most active towards the added substrate in the extract. Lysis
of cells means that sub-cellular compartmentation is disrupted,
and the use of artificial substrates means that scaffolding and
regulatory functions of protein complexes may be impaired.
Nevertheless, this criticism also applies to other biochemical
approaches and certainly to in silico methods, and it can be
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Fig. 7 KiPIK correlation coefficients for known kinases displayed on human kinome dendrograms. a H3T3ph results from the PKIS1/DSF dataset. b
H3S28ph results from the PKIS1/Nanosyn 1 µM dataset. c Integrin β1 A Y795ph results from the PKIS1/Nanosyn 1 µM dataset. d EGFR Y1016ph results
from the PKIS1/Nanosyn 1 µM dataset. Circle sizes indicate correlation coefficients (from no circle at ρ= 0 to the largest circle at ρ= 1). The expected
kinase, and overall top hit in each screen, is shown in deep violet. Trees for all results can be found in Supplementary Figs. 13–18. Kinome trees were
produced using KinMap92, and the underlying tree illustration is reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). Source data
are provided as a Source Data file.
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addressed by using recombinant proteins or protein complexes as
substrates in KiPIK, and sub-cellular fractionation could be used
to focus screening on particular compartments. We argue that
KiPIK is less sensitive to indirect effects than screens using intact
cells, but this may vary from case to case. In common with all
screening methods, follow up experiments are required to con-
firm the relevance of candidate kinases. Finally, when more than
one kinase phosphorylates the substrate to a significant extent,
and these kinases have similar inhibition profiles, KiPIK may be
able to reveal candidate kinases that are masked by redundancy in
genetic screens (see Fig. 6). However, when kinases with distinct
inhibition profiles are involved, then KiPIK in its current form
may not always be able to resolve the relevant candidate kinases.
Whether such signals can be deconvoluted computationally is an
interesting question for further work. Possible approaches have
been tried, with varying success, to understand the contributions
of multiple kinases to cellular phenotypes using kinase inhibitor
screens77–81.
We can envision several other ways in which KiPIK can be
extended and improved in the future. For example, larger inhi-
bitor libraries would allow more robust identification of kinases
with little increase in the time required. The use of single-step
homogenous kinase assays rather than ELISAs could streamline
the procedure, and alternative detection approaches would allow
for multiplexing and/or reduce the need for phosphosite-specific
antibodies. For example, the use of high-throughput mass spec-
trometry would allow multiple phosphorylation sites on one or
more substrates to be monitored simultaneously without requir-
ing antibodies28. It should also be possible to expand the sources
of extract used for screening. For example, organoid cultures
might provide a more physiological source of cells, and patient-
derived material such as blood cells or biopsies might be used to
conduct KiPIK screens to obtain insight into disease, such as
mechanisms of resistance to therapeutics in cancer. Profiling
panels including larger numbers of disease-relevant mutant
kinases could also be developed. Given the low proportion of
known phosphorylation sites for which kinases are known, and
the critical role of kinase signaling in biology and drug devel-
opment, we expect the method to find wide application.
Methods
Cell culture. HeLa (ATCC CCL 2.2) and A431 (ATCC CCR-1555) cells were
grown in DMEM with 5% (v/v) FBS and 100 U/ml penicillin–streptomycin, at
37 °C and 5% CO2 in a humidified incubator.
Antibodies. For KiPIK screening, immunoblotting and immunofluorescence
microscopy, rabbit polyclonal antibodies to H3T3ph (B8634)47, INCENP (P240, Cell
Signaling Technology #2807), INCENP-S446ph (Jan-Michael Peters, IMP, Vienna)57,
INCENP-TSSph (Michael Lampson, University of Pennsylvania)82, BCL9L S915ph
(Cell Signaling Technology #13325), Neurogranin S36ph (Merck-Millipore, ABN426)
and γ-tubulin (AK-15, Sigma, T3320); rabbit monoclonal antibodies to the S-pT-P
motif (D73F6; Cell Signaling Technology #5243), Cyclin B1 (D5C10; Cell Signaling
Technology #12231) and Vinculin (E1E9V; Cell Signaling Technology #13901);
mouse monoclonal antibodies to H3S28ph (CMA315)83 and phospho-tyrosine (P-
Tyr-100; Cell Signaling Technology #9411); and sheep polyclonal antibodies to
Aurora B (SAB.1, Stephen Taylor, University of Manchester)84 and BCL9L (R&D
Systems, AF4967) were used. Antibodies used for siRNA screening were mouse
monoclonal anti-H3T3ph (16B2)85 and rabbit polyclonal anti-H2BS6ph86. Secondary
antibodies were: donkey anti-sheep IgG-HRP (ThermoFisher, A16041), goat anti-
rabbit IgG-HRP (Cell Signaling Technology #7074), horse anti-mouse IgG-HRP (Cell
Signaling Technology #7076), donkey anti-mouse Alexa Fluor 488, anti-rabbit Alexa
Fluor 594 and anti-sheep Alexa 488 Fluor (ThermoFisher, A-21202, A-21207, and A-
11015).
Small molecules and peptides. KiPIK inhibitor details are provided in Supple-
mentary Data 2–4. Additional compounds used were Forskolin and ZM447439
(Tocris Biosciences), RO-3306 (Calbiochem), H-89 (BioMol International), SU-
14813 (Cambridge Biosciences) and MK-2206 (Cayman Chemical).
BCL9L(908–922) peptide: biotin-RGLGRRPSDLTISIN (custom, Eurogentec).
EGFR peptide: biotin-ADEYLIPQQ (AS-29942-1, Eurogentec).
H3(1–21) peptide: ARTKQTARKSTGGKAPRKQLA-GGK-biotin (custom,
Abgent).
H3(21–44) peptide: ATKAARKSAPATGGVKKPHRYRPG-GK-biotin (AS-
64440, Eurogentec).
INCENP peptide: biotin-GPREPPQSARRKRSY (custom, Eurogentec).
Integrin β1A tail peptide: biotin-GG-KSAVTTVVNPKYEGK (custom,
Eurogentec).
Neurogranin(28–43) peptide: biotin-LC-AAKIQASFRGHMARKK (101472-
001, Mimotopes).
Preparation of KiPIK cell extracts. To prepare mitotic cell extract, HeLa cells were
treated with 300 nM nocodazole for 9 h and then collected by shake off. To prepare
TPA-stimulated cell extracts, HeLa cells were treated with 200 nM TPA for 30min.
To prepare EGF-stimulated cell extracts, A431 cells were trypsinised, collected in
prewarmed DMEM supplemented with 50 ng/ml human EGF (Cell Signalling
Technology) and incubated at 37 °C for 5 min. After these treatments, cells were
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Fig. 8 KiPIK correlation coefficients for unknown kinases displayed on human kinome dendrograms. a INCENP S446ph results from the PKIS1/DSF
dataset. b BCL9L S915ph results from the PKIS2/Repeat 2 dataset. Circle sizes indicate correlation coefficients (from no circle at ρ= 0 to the largest circle
at ρ= 1). For A, strong hits on the CDK kinase branch are shown in green. For B, the top hit is shown in deep violet. Trees for all results can be found in
Supplementary Figs. 19 and 20. Kinome trees were produced using KinMap92, and the underlying tree illustration is reproduced courtesy of Cell Signaling
Technology, Inc. (www.cellsignal.com). Source data are provided as a Source Data file.
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washed once with PBS and lysed at 4 °C in 50mM Tris, 0.25M NaCl, 0.1% Triton
X100, 10mM MgCl2, 2 mM EDTA, 1 mM DTT, pH 7.5 with protease inhibitor
cocktail (Sigma P8340), PhosSTOP (Merck), 1 mM PMSF, 0.1 µM okadaic acid,
10 mM NaF, 20mM β-glycerophosphate, at approximately 30 × 106 cells/ml.
Extracts were immediately flash frozen in liquid nitrogen.
KiPIK screens. Kinase reactions contained 10 µM kinase inhibitor or DMSO
(vehicle control), 0.1–0.35 µM peptide, 0.2–0.7 mM ATP, 0.5–5% cell extract, in
KiPIK buffer (50 mM Tris, 10 mM MgCl2, 1 mM EGTA, 10 mM NaF, 20 mM β-
glycerophosphate, 1 mM PMSF, pH 7.5 with PhosSTOP (Merck). Reactions were
carried out in duplicate in 384-well microplates (ThermoFisher), at 30 °C for 30
min, in a total volume of 35 µl/well.
For detection of phosphorylation, High Capacity Streptavidin-coated 384-well
plates (Pierce) were washed thrice with TBS, 0.05% Tween20. In some cases, 10 µl/
well of 500mM EDTA was added. Then, 35 µl/well of completed KiPIK extract kinase
reaction was added and incubated at room temperature for 2 h. After washing,
primary phospho-specific antibodies were added at 40 µl/well in TBS, 0.05% Tween20,
0.1% BSA, for 2 h at room temperature (H3S28ph 0.2 µg/ml, H3T3ph 0.1 µg/ml, P-
Tyr-100 0.15 µg/ml, INCENP S446ph 1:5000, BCL9L S915ph 1:5000). After washing,
40 µl/well of HRP-conjugated secondary antibodies in TBS, 0.05% Tween20, 0.1%
BSA were added for 1 h at room temperature. After washing, HRP-conjugated
antibody binding (1:3000) was detected using TMB substrate (New England Biolabs)
according to the manufacturer’s instructions. All pipetting was performed with a
Biomek FX liquid handling robot (Beckman Coulter). Absorbance readings were
made using a Polarstar Omega microplate reader (BMG Labtech).
Analysis of KiPIK results. Using the mean of duplicate determinations, a standard
score was calculated for each inhibitor treatment where standard score= (mean
absorbance in presence of inhibitor - mean absorbance of multiple DMSO con-
trols)/standard deviation of DMSO controls. The inhibitory effect of each com-
pound was defined as follows: %inhibition= 100 × (standard score for inhibitor/
lowest standard score on plate). The lowest standard score on the plate was either
from the EDTA-treated control wells or from those containing the most inhibitory
compound. The %inhibition scores for all inhibitors were then compiled as the
inhibition fingerprint of the phosphorylation event probed. Using Prism (Graph-
Pad), Pearson’s correlation (ρ) was then calculated for this fingerprint against the
inhibition profiles of each of the kinases profiled in vitro against that inhibitor
library, excluding mutant kinases. Notably, because Davis et al. determined Kd
values for each kinase-inhibitor interaction in their panels, rather than single point
percent inhibition values33, we made estimates of the %inhibition expected at
0.5 µM, using the Hill equation: %inhibition= 100/(1+ (Kd/500)). To calculate z-
scores, we used a VBA macro in Excel (Microsoft) to permutate inhibitor name
labels and generate 100 randomised sets of %inhibition results. From these, we
calculated 100 sets of Pearson correlation coefficients to estimate the null dis-
tribution of correlation coefficients for that screen (Supplementary Fig. 11A). We
then calculated z-scores where z= (observed ρ−mean ρ of null distribution)/
standard deviation of null distribution.
Inhibitor downsampling and cluster analysis. To investigate how robust KiPIK
results were to the size of the inhibitor library used, we downsampled inhibitor
libraries and tested how easy it was to identify true hits using the downsampled
versions. From existing libraries of size N, we repeatedly sampled (without repla-
cement) n inhibitors and checked how many times the true hit was contained in
the top k kinases ranked by correlation with the unknown kinase (Pearson’s cor-
relation coefficient, calculated using the cor function in R). By setting k= 1, 5 or 10
(or k ≈N/100, N/20 or N/10) and setting n= 3,…,N and sampling 10,000 times, we
generated curves representing how the uncertainty in hit identification varies with
library size.
For hierarchical clustering of inhibition fingerprints, we used hclust and
heatmap in the ComplexHeatmap v1.10.2 package87 implemented in R version
3.4.0 (2017–04–21)88, calculating distances using (1− Pearson correlation
coefficient) and clustering using the method Ward.D289. For bootstrapping, we
used hclust within pvclust package 4 with 10,000 iterations, producing two types of
p-value: Approximately Unbiased (AU) p-value and Bootstrap Probability (BP)
value. The AU value is considered the best indication of robustness90.
Kinome siRNA screen. Hela cells were grown in clear-bottomed microplates
(uClear 384 well microplates, Greiner). Transfection was carried out using
Interferin-HTS (Polyplus), according to the manufacturer’s instructions. The
siRNA library targeted 840 genes from the Dharmacon Human Druggable
siGENOME library, of which 712 were kinase-related, 110 were G-protein coupled
receptor-related and 18 were phosphatase-related. After 24 h, cells were accumu-
lated in mitosis for 6 h by addition of 200 nM nocodazole, immunofluorescently
stained with mouse anti-H3T3ph (0.1 µg/ml) and rabbit anti-H2BS6ph antibodies
(1:1000), followed by fluorophore-conjugated secondary antibodies, and the
intensity of staining quantified by High Content Imaging. Experiments were car-
ried out in quadruplicate. The standard score for condition was then calculated,
where standard score= (mean staining intensity in presence of siRNA−mean
staining intensity for entire plate)/standard deviation of staining intensity for the
entire plate; p-values were calculated using one-sample t-test for each siRNA
treatment. Approximately 300 cells were measured for each siRNA treatment.
Immunofluorescence. Cells were fixed for 10 min with 2% paraformaldehyde in
PBS, washed twice in PBS, then permeabilized for 2 min with 0.5% Triton X100,
PBS. After washing twice in PBS, cells were incubated for 1 h in 5% milk in PBS,
0.05% Tween20 at room temperature, and then with primary antibodies at 37 °C in
5% milk in PBS, 0.05% Tween20 (Aurora B 1:2000, INCENP S446ph 1:2000,
INCENP TSSph 1:1000). After washing twice with PBS, 0.05% Tween20, and twice
with PBS, cells were incubated for 45 min with 2 µg/ml fluorophore-conjugated
secondary antibodies at 37 °C in 5% milk in PBS, 0.05% Tween20. After washing
twice with PBS, 0.05% Tween20, twice with PBS, and once with milliQ H2O,
samples were mounted using Prolong Gold (Invitrogen) for cover slips, or
Fluoromount-G with DAPI (Invitrogen) for microplates.
Microscopy. For High Content imaging of cells in microplates, the average
fluorescence intensity (integrated) of mitotic cells (defined as cells positive for
either stained mitotic histone mark) was measured using a widefield Nikon Eclipse
Ti-E microscope equipped with an automated stage, DS-Qi1MC camera (Nikon)
and High Content Analysis software (Nikon Elements with JOBS 4.12) using a Plan
Apo Lambda 20x/0.8 objective and 1.5x internal magnification. Cells on coverslips
were imaged with a Zeiss AxioImager Z2 microscope using a Plan-Apochromat
100x/1.40 oil objective and ZEN 2.3 software (Zeiss). Optical sections were
acquired every 0.1 µm using an AxioCam MR R3 camera. Image stacks are dis-
played as maximum intensity projections.
Recombinant proteins. GST-CDK1/GST-CycB kinase was from Cell Signaling
Technology (#7518), PKA-α from Millipore (14-440), PKC-δ from Promega
(V3401), and Aurora B/INbox(825–918) from Millipore (14-835). Purified
recombinant fragments of INCENP were from Novus Biologicals (pPEPTIDE-
INCENP(369–583); NBP2-37471CUSTOM) and Upstate Biotechnology (GST-
INCENP(825–918); 12-534). Purified full length INCENP-Aurora B complex was
produced using the plasmid pGEX-hAurora B-rbs-hINCENP91 with a 6xHis
coding sequence added to the 3′-end. Expression in E. coli strain BL21-CodonPlus
DE3 (Agilent Technologies) was induced with 1 mM IPTG for 20 h at 18 °C.
Bacterial pellets were resuspended in lysis buffer (20 mM Tris-HCl, 0.5 M NaCl, 1
mM DTT, pH 8) with cOmplete™ Mini EDTA-free Protease Inhibitors (Merck).
Cells were lysed by sonication, polyethylenimine was added to precipitate cellular
debris and, after centrifugation twice at 3600 g for 5 min, the supernatant was
incubated with glutathione Sepharose 4B resin (GE Life Sciences) for 15 min. After
washing with 5 volumes of lysis buffer, the resin was incubated for 10 min in lysis
buffer containing 5 mM ATP, 5 mM MgCl2 to eliminate bacterial chaperones.
Recombinant proteins were then eluted with 150 mM Tris-HCl, 0.5 M NaCl, 1 mM
DTT, 50 mM reduced glutathione, pH 9.2 and dialysed into 50 mM Tris-HCl, 0.3
M NaCl, 0.5 mM EDTA, 1 mM DTT, pH 8 overnight at 4 °C, in the presence of
PreScission protease (Merck) to cleave GST. Following a second dialysis into 20
mM NaPO4, 75 mM NaCl, pH 7 at 4 °C for 4 h, and removal of precipitates by
centrifugation at 3600 × g for 5 min, free GST was removed by adding glutathione
Sepharose 4B. Recombinant proteins were further purified by ion exchange chro-
matography (Q Sepharose; GE Life Sciences), elution with increasing concentration
of NaCl, and then dialysis into 20 mM NaPO4, 150 mM NaCl, 1 mM DTT, pH 7.
Finally, purified INCENP-Aurora B was treated with λ phosphatase (New England
Biolabs) to remove existing phosphorylation.
In vitro kinase reactions. When using INCENP fragments as substrates, reactions
were carried out in 20 mM HEPES, 1 mM ATP, 5 mM MgCl2, 0.14M NaCl, 3 mM
KCl, pH 7.4 with ~100 nM of each substrate and 10 nM of recombinant kinase for
30 min at 30 °C. When using full length INCENP-Aurora B substrate, reactions
were carried out in 50 mM Tris, 1 mM ATP, 10 mM MgCl2, 1 mM EGTA, 10 mM
NaF, 20 mM β-glycerophosphate, pH 7.5 with PhosSTOP phosphatase inhibitors
(Merck) and approximately 70 nM of INCENP substrate and 7 nM of recombinant
Cyclin B1-Cdk1 for 30 min at 37 °C. Aurora B inhibitor ZM447439 was included at
0.5 µM. To assay full-length BCL9L phosphorylation, HeLa cells lysed in 50 mM
Tris, 0.15M NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate, pH 7.5,
with 2.5 U/µl Benzonase (Merck) and cOmplete™ Protease Inhibitor Cocktail
(Roche) were subjected to immunoprecipitation with 5 µg/ml anti-BCL9L anti-
bodies and Dynabeads Protein G (ThermoFisher). After 1 h, beads were washed
three times in PBS, split into 3 equal fractions and incubated with 1 nM PKA-α or
PKC-δ, or without kinase, at 1 mM ATP in the conditions described above for
peptides. After washing, bound proteins were eluted by boiling in SDS-PAGE
sample buffer and analyzed by immunoblotting. When using peptide substrates,
reactions were carried out at 37 °C for 30 min with 0.1 µM peptide and 0.1 mM
ATP and either PKC-α in 50 mM Tris, 10 mM MgCl2, 1 mM EGTA, 10 mM NaF
and 20 mM β-glycerolphosphate, pH 7.5, or with PKC-δ in 40 mM Tris, 20 mM
MgCl2, 0.1 mg/ml BSA, 50 μM DTT, 50 µg/ml phosphatidylserine, 5 µg/ml 1-
stearoyl-2-linoleoyl-sn-glycerol, 5 µg/ml 1-oleoyl-2-acetyl-sn-glycerol, pH 7.5, and
phosphorylation was detected using antibodies as described for KiPIK screens
(BCL9L S915ph 1:1000, Neurogranin S36ph 1:1000).
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INCENP immunoprecipitation. HeLa 1C8 cells47 were treated with 0.5 µg/ml
nocodazole for 8 h. After collecting mitotic cells by shake off and replating, either
100 µM Roscovitine or DMSO (vehicle control) was added together with 20 µM
MG132 in the continued presence of nocodazole. After 2 h, cell lysates were pre-
pared in 50 mM Tris, 0.3 M NaCl, 0.5% Triton X-100, 10 mMMgCl2, 5 mM EDTA,
1 mM dithiothreitol, 1 mM PMSF, 0.1 μM okadaic acid, 10 mM NaF, 20 mM β-
glycerophosphate, 0.25 U/µl Benzonase, cOmplete™ Mini EDTA-free Protease
Inhibitors (Merck), pH7.4 and subjected to immunoprecipitation with rabbit anti-
INCENP (diluted 1:30) and Dynabeads Protein G (ThermoFisher). After washing,
bound proteins were eluted by boiling in SDS-PAGE sample buffer.
RNAi and inhibitor treatment of cells. HeLa cells were transfected with 50 nM
Mission siRNAs using Lipofectamine RNAiMAX according to the manu-
facturer’s instructions (ThermoFisher). After 48 h, cells were treated with 200
nM TPA for 30 min before lysis in NuPAGE loading buffer (ThermoFisher)
containing 100 mM DTT, 0.25 U/µl Benzonase, and PhosSTOP (Merck). The
siRNAs were: BCL9L, EH054121; AKT1, EHU083501; AKT3, EHU067201;
PKA-α, EHU132541; PKA-β, EHU075621; PKC-δ, EHU067081; PKC-ε,
SIHK1828; PKC-η, SIHK1833; PKG1 #1, SIHK1862; PKG1 #5, SIHK1866; PKG2
#1, SIHK1867; PKG2 #2, SIHK1868; LATS2, SIHK1044 (Sigma-Aldrich).
Alternatively, cells were treated with 200 nM TPA or 10 µM Forskolin for var-
ious time periods, or were pretreated with 0.5 µM SU-14813, 0.2 µM Gö 6983, 30
µM H-89 or 10 µM MK-2206 for 30 min and then stimulated with 200 nM TPA
for 30 min before lysis in 50 mM Tris, 0.15 M NaCl, 0.1% SDS, 1% Triton X-100,
0.5% sodium deoxycholate, pH 7.5, with 2.5 U/µl Benzonase (Merck) and
cOmplete™ Protease Inhibitor Cocktail (Roche).
SDS-PAGE and immunoblotting. SDS-PAGE was carried out using the NuPAGE
Bis-Tris (ThermoFisher) or BioRad systems. Proteins were transferred onto PVDF or
Nitrocellulose membranes using standard techniques. Membranes were blocked with
3–5%milk in TBS, 0.1% Tween20 for 1 h, then with primary antibodies in 3–5% milk,
TBS, 0.1% Tween20 overnight at 4 °C (INCENP 1:1000, INCENP S446ph 1:1000,
INCENP TSSph 1:1000, BCL9L 0.4 µg/ml, BCL9L S915ph 1:1000, Vinculin 1:1000,
Cyclin B1 1:1000, S-pT-P 1:1000, γ-tubulin 8 µg/ml). After washing 3 times with TBS,
0.1% Tween20, they were incubated for 1 h with HRP-conjugated secondary anti-
bodies (1:10,000) in 3–5% milk, TBS, 0.1% Tween20, washed three times with TBS,
0.1% Tween20 and once with TBS, before development using ECL substrate (Pierce or
GE Healthcare) and exposure to X-ray film. Stripping of immunoblots was carried out
with Restore Western Blot Stripping Buffer (ThermoFisher).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the authors. The source data underlying Figs. 2, 3,
4a–c, 5–8 and Supplementary Figs. 2–8 and 11–20 are provided as a Source Data file.
Data for Supplementary Figs. 9, 10, and 21–32 can also be found at https://github.com/
CnrLwlss/Watson_2020.
Code availability
R source code can be found at https://github.com/CnrLwlss/Watson_2020 and the VBA
Shuffler code is provided in the Source Data file.
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